Century Therapeutics, Inc. officer Douglas Carr filed a Form 144 notice on November 3, 2026, proposing to sell 266 shares of Century Therapeutics common stock on NASDAQ, with an aggregate market value of $403.94.

Key Highlights

  • Proposed sale: Douglas Carr, an officer of Century Therapeutics, Inc., intends to sell 266 shares of common stock with an aggregate market value of $403.94.
  • Source of shares: The 266 shares were acquired on November 2, 2026, through a restricted stock vesting event, with payment classified as compensation.
  • Approximate sale date: The filing lists November 3, 2026, as the approximate date of sale, with Fidelity Brokerage Services LLC named as the executing broker.
  • Shares outstanding: According to the filing, Century Therapeutics had 181,075,321 shares of common stock outstanding at the time of the notice.
  • Prior three-month sales: The filing discloses that Carr sold 275 shares on August 3, 2026 (gross proceeds $543.73), 254 shares on September 8, 2026 (gross proceeds $520.57), and 1,658 shares on September 14, 2026 (gross proceeds $3,200.77).
  • Tax-related purpose: The filing states the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

Century Therapeutics Officer Carr Proposes Tax-Related Share Sale After Restricted Stock Vesting

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 3, 2026, Douglas Carr, an officer of Century Therapeutics, Inc. (NASDAQ:IPSC), disclosed a proposed sale of 266 shares of the company's common stock. The filing identifies Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, as the named broker for the transaction. The aggregate market value of the proposed sale is listed as $403.94.

The filing discloses that the 266 shares were acquired on November 2, 2026, through a restricted stock vesting event from the issuer, with the nature of payment listed as compensation. The remarks section of the notice states that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," providing the stated rationale for the proposed transaction. The filing was signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Douglas Carr.

As required by Form 144, the filing also discloses Carr's sales of Century Therapeutics common stock during the prior three months. Those transactions included a sale of 275 shares on August 3, 2026, generating gross proceeds of $543.73; a sale of 254 shares on September 8, 2026, generating gross proceeds of $520.57; and a sale of 1,658 shares on September 14, 2026, generating gross proceeds of $3,200.77. Century Therapeutics is headquartered at 25 N 38th Street, 12th Floor, Philadelphia, Pennsylvania 19104, and its SEC file number is listed as 001-40498.

What Was Disclosed

Douglas Carr, an officer of Century Therapeutics, Inc., filed a Form 144 notice on November 3, 2026, proposing to sell 266 shares of common stock valued at $403.94 in aggregate, acquired through restricted stock vesting the prior day, with the stated purpose of covering a tax obligation.